Abstract
Taxane-associated maculopathy is scarcely reported in the literature but should be considered as a known complication of intravenous use of the chemotherapy medication to ophthalmologists as well as primary care physicians and oncologists. We report a case of paclitaxel maculopathy in a 61-year-old female who received treatment with this drug for metastatic breast cancer. This is the first known case to report complete resolution of the maculopathy after cessation of the drug.
Copyright 2013, SLACK Incorporated.
MeSH terms
-
Antineoplastic Agents, Phytogenic / adverse effects*
-
Biomarkers, Tumor / analysis
-
Breast Neoplasms / chemistry
-
Breast Neoplasms / drug therapy
-
Breast Neoplasms / pathology
-
Carcinoma, Ductal, Breast / chemistry
-
Carcinoma, Ductal, Breast / drug therapy
-
Carcinoma, Ductal, Breast / secondary
-
Female
-
Fluorescein Angiography
-
Humans
-
Lung Neoplasms / chemistry
-
Lung Neoplasms / drug therapy
-
Lung Neoplasms / secondary
-
Lymphatic Metastasis
-
Macular Edema / chemically induced*
-
Macular Edema / diagnosis
-
Macular Edema / physiopathology
-
Middle Aged
-
Paclitaxel / adverse effects*
-
Tomography, Optical Coherence
-
Visual Acuity / physiology
Substances
-
Antineoplastic Agents, Phytogenic
-
Biomarkers, Tumor
-
Paclitaxel